Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Zynex, Inc.

Zynex Medical develops and provides non-invasive medical devices for pain management and muscle rehabilitation.  The self-described leading provider offers a range of products including TENS/IFC/NMES devices and braces for various body parts.

Metric
Company Name	Zynex, Inc.
Symbol	ZYXI
MSH ID	COM:ZYNEX
Market	STOCKS
Sector	Healthcare
Industry	Medical - Distribution
Country	US
Stage
Employee Count	1.10K
Website	zynex.com
LinkedIn
Founders

Metric
Market Cap	285.34M
Enterprise Value
Monthly Web Traffic	39.24K
Web Traffic Growth	3.20
Valuation
Raised Capital	52.50M

Metric
Revenue	184.32M
Revenue (LTM)
Revenue (NTM)
Gross Profit	145.96M
EBITDA	15M
Operating Income	10.78M
Net Income	9.73M
EPS	0.27
Diluted EPS	0.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.80
Operating Profit Margin	0.07
EBITDA Margin	0.08
Net Profit Margin	0.05
Return on Equity	0.17
Return on Assets	0.07
Return on Capital Employed	0.11

COM:ZYNEX

Zynex Medical

Last Close

8.11

22/11 21:00

Market Cap

285.34M

Beta: -

Volume Today

63.59K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	26.14
P/B Ratio	7.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.25
EV Multiple	23.40

Metric
Days Sales Outstanding	65.38
Days Payables Outstanding	78.39
Days Inventory Outstanding	147.13
Operating Cycle	196.34
Cash Conversion Cycle	196.34
Asset Turnover	1.59

Metric
Operating Cash Flow	17.95M
Free Cash Flow	16.74M
Cash Flow to Debt	0.30
Operating Cash Flow/Sales	0.10
Free Cash Flow Yield	0.04

Metric
Cash & Equivalents	44.58M
Accounts Receivable	8.22M
Inventory	13.11M
Goodwill	20.40M
Debt to Capitalization	0.70
Debt to Assets	0.50
Current Ratio	5.19
Quick Ratio	3.85

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue
SG&A to Revenue	0.25